Drug intelligence / Profile preview

PNC-005

Development stage: Preclinical
Lead developer: ProEncia Biotechnology
Modality: Small Molecules
Administration: Topical

Overview

PNC-005 is a topical therapeutic candidate developed by ProEncia Biotechnology for the treatment of mild-to-severe periodontal disease. Positioned as an over-the-counter (OTC) product, it is designed for local application to the gingival tissues to manage inflammation and bacterial infection associated with periodontitis. The drug is part of ProEncia's pipeline of oral health products, which includes both OTC and prescription (RX) formulations (such as PNC-007 and PNC-009) aimed at addressing various stages of periodontal conditions.

Beyond the preview

Go deeper on PNC-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNC-005.

Explore the full profile